NSE/AUROPHARMA (NSE/AUROPHARMA)

National Stock Exchange of India: NSE/AUROPHARMA · INR

₹1,645

+17.25 (+1.1%)· Recorded snapshot

Market cap	946.4B
Revenue (ttm)	349.4B
Net income (ttm)	37.1B
EPS (ttm)	₹64.0
Shares out	575.4M
P/E (trailing)	25.7x
P/E (forward)	20.0x
Dividend	₹8.00 (0.49%)
Volume	568,761
Beta	0.03

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 349.4B
Net income (ttm): 37.1B
EPS (ttm): ₹64.0
P/E (trailing): 25.7x
P/E (forward): 20.0x
Market cap: 946.4B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E20

P25 n/aP50 n/aP75 n/a

Trailing P/E25.7

P25 n/aP50 n/aP75 n/a

ROE9.9

P25 n/aP50 n/aP75 n/a

ROIC10.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NSE/AUROPHARMA indicators

Market & fundamental data

Available fields

246

Groups with data

Currency

INR

Showing 246 of 246 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	INR
Country	India
Country code	IN
Earnings date	2026-11-04
Employees	29,209
Employees change	1,502
Employees growth	5.42%
Enterprise value	INR 921.2B
Exchange	National Stock Exchange of India
Financial currency	INR
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	March
Founded	1986
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
ISIN number	INE406A01037
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split date	2015-07-20
Last stock split type	Forward
Market cap	INR 946.4B
Next earnings date	2026-11-04
Price	INR 1,644.80
Price currency	INR
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	nse/AUROPHARMA
Website	https://www.aurobindo.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	25.55x
Average P/E ratio (10Y)	16.78x
Average P/E ratio (3Y)	21.25x
Average P/E ratio (5Y)	18.49x
Earnings yield	3.89%
EV/Earnings	24.81x
EV/EBIT	17.23x
EV/EBITDA	12.97x
EV/FCF	32.43x
EV/Sales	2.64x
FCF / EV yield	3.08%
FCF yield	3%
Forward P/E	20.02x
Graham number	969.18423
Graham upside	-41.08%
Industry forward P/E	33.08x
Industry P/E	38.9x
Lynch fair value	INR 319.96
Lynch upside	-80.55%
P/B ratio	2.5x
P/E ratio	25.7x
P/FCF ratio	33.32x
P/OCF ratio	17.12x
P/S ratio	2.71x
PEG ratio	1.07x
Price / tangible book value	2.89x
Price/EBITDA ratio	13.48x
Sector forward P/E	36.12x
Sector P/E	45.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.31%
EBITDA margin	20.1%
Effective tax rate	31.54%
FCF margin	8.44%
Gross margin	58.85%
Operating margin	15.31%
Pretax margin	15.51%
Profit margin	10.63%
Profit per employee	INR 1.3M
Profitable quarters	56
Profitable years	14
Revenue per employee	INR 12M
ROA	5.95%
ROA (5Y)	5.88%
ROCE	12.73%
ROE	9.93%
ROE (5Y)	10.23%
ROIC	10.35%
ROIC (5Y)	10.4%
Tax / revenue	4.89%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	9.73%
EPS growth (Q)	25.78%
EPS growth (QoQ)	12.63%
EPS growth 10Y	5.97%
EPS growth 3Y	23.76%
EPS growth 5Y	-6.78%
EPS growth quarters	4
EPS growth years	3
FCF growth	45.17%
FCF growth 5Y	8.48%
Gross profit growth	9.18%
Gross profit growth (Q)	19.32%
Gross profit growth 3Y	14.88%
Gross profit growth 5Y	7.38%
Net income growth	9.47%
Net income growth (Q)	25.2%
Net income growth (QoQ)	12.08%
Net income growth 3Y	23.36%
Net income growth 5Y	-6.95%
Net income growth quarters	4
Net income growth years	3
OCF growth	40.81%
OCF growth 10Y	14.56%
OCF growth 3Y	32.3%
OCF growth 5Y	10.67%
Operating income growth	8.29%
Operating income growth (Q)	16.41%
Operating income growth 3Y	25.72%
Operating income growth 5Y	4.07%
Revenue growth	9.09%
Revenue growth (Q)	16.3%
Revenue growth (QoQ)	3.35%
Revenue growth 10Y	9.31%
Revenue growth 3Y	11.11%
Revenue growth 5Y	7.31%
Revenue growth quarters	15
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	INR -26.9B
Depreciation and amortization	INR 16.7B
EBIT	INR 53.5B
EBITDA	INR 70.2B
EPS	INR 63.99
FCF per share	INR 49.37
Financing cash flow	INR -12.7B
Free cash flow	INR 28.4B
Gross profit	INR 205.6B
Income taxes	INR 17.1B
Investing cash flow	INR -34.6B
Net borrowing	INR -6.9B
Net cash flow	INR 16.3B
Net income	INR 37.1B
Operating income	INR 53.5B
Revenue	INR 349.4B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	INR 652.39
Debt / EBITDA	1.14
Debt / equity	0.21
Debt / FCF	2.84
Interest coverage	15.01
Net cash (debt)	INR 25.1B
Net cash / market cap	2.65%
Net debt / EBITDA	-0.36
Net debt / equity	-0.07
Net debt / FCF	-0.88
Piotroski F-Score	5
Shareholders' equity	INR 378.8B
Tangible book value	INR 327.9B
Tangible book value per share	INR 564.55
Total cash	INR 105.8B
Total debt	INR 80.7B
WACC	4.31%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.62
Current ratio	1.81
Inventory turnover	1.24
Quick ratio	1
Working capital	INR 146.7B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.25%
Dividend growth (10Y)	7.18%
Dividend growth (3Y)	-23.69%
Dividend growth (5Y)	-1.21%
Dividend growth years	1
Dividend payment date	2025-08-21
Dividend payment years	25
Dividend per share	INR 8.00
Dividend yield	0.49%
Ex-dividend date	2025-08-08
Last dividend	INR 4.00
Shareholder yield	0.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	103.59%
10Y return CAGR	7.92%
10Y total return	114.31%
150-day SMA	INR 1,538.56
15Y price change	2,553.97%
15Y return CAGR	25.13%
15Y total return	2,787.62%
1D price change	1.06%
1M price change	-3.93%
1M total return	-3.93%
1W price change	1.44%
1W total return	1.44%
1Y price change	50.25%
1Y return CAGR	50.29%
1Y total return	50.25%
20-day SMA	INR 1,653.93
200-day SMA	INR 1,452.96
20Y price change	2,625.66%
20Y return CAGR	18.78%
20Y total return	3,025.9%
3M price change	6.16%
3M total return	6.16%
3Y price change	92.5%
3Y return CAGR	24.73%
3Y total return	94.08%
50-day SMA	INR 1,661.22
50-day SMA vs 200-day SMA	50over200
52-week high	INR 1,740.00
52-week high date	2026-09-24
52-week low	INR 1,081.40
52-week low date	2025-10-28
5Y price change	132.78%
5Y return CAGR	19.06%
5Y total return	139.25%
6M price change	16.1%
6M total return	16.1%
All-time high	INR 1,740.00
All-time high date	2026-09-24
All-time low	INR 10.13
All-time low date	2008-11-06
Average true range (ATR)	INR 44.01
Average volume	871.7K
Beta (1Y)	0.15
Beta (2Y)	0.4
Beta (5Y)	0.03
Change from 52-week high	-5.47%
Change from 52-week low	52.1%
Change from all-time high	-5.47%
Change from all-time low	16,144.94%
Change from open	1.22%
Day's gap	-0.15%
Dollar volume	INR 935.5M
High price	INR 1,650.00
Low price	INR 1,609.10
Monthly RSI	68.41
Open price	INR 1,625.00
Position in 52-week range	87.29%
Previous close	INR 1,627.50
Price vs 150-day SMA	6.9%
Price vs 20-day SMA	-0.55%
Price vs 200-day SMA	13.2%
Price vs 50-day SMA	-0.99%
Relative volume	0.66
RSI	49.33
Sharpe ratio	1.52
Sharpe ratio (3Y)	0.73
Sharpe ratio (5Y)	0.59
Sortino ratio	2.61
Sortino ratio (3Y)	1.32
Sortino ratio (5Y)	1.09
Volume	568.8K
Weekly RSI	58.77
YTD price change	39.04%
YTD total return	39.04%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	273.5M
Shares change (QoQ)	-0.47%
Shares change (YoY)	-0.25%
Shares held by insiders	15.36%
Shares held by institutions	32.31%
Shares outstanding	575.4M

Deeper analysis on NSE/AUROPHARMA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NSE/AUROPHARMA report

Is a complete NSE/AUROPHARMA research report available?

No complete published report is available for nse/AUROPHARMA (NSE/AUROPHARMA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NSE/AUROPHARMA (NSE/AUROPHARMA)

Price

Financial snapshot

Fair-value bridge

Latest news · NSE/AUROPHARMA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NSE/AUROPHARMA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NSE/AUROPHARMA

Frequently asked questions